AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

AstraZeneca’s (AZN) second-quarter 2024 core earnings of 99 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 96 cents. Core earnings of $1.98 per share fell 8% year over year on a reported basis and 3% at constant exchange rates (CER).Total revenues of $12.94 billion rose 13% on a reported basis and 17% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $12.48 billion.All ...